GlassScriptPhysician profile
Max F Adler
NPI 1801835434
$26,082.22
in general payments reported to CMS, 2019-2025
37 companies · $3,486 in 2025
The $3,486 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $967 · 2020: $14K · 2021: $592 · 2022: $1,010 · 2023: $3,078 · 2024: $2,925 · 2025: $3,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,381 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,381.38 |
| Education | $108.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $14,724.98 | 2019-2022 | |
| Abbvie INC. | $2,787.11 | 2022-2025 | Skyrizi, Humira, Rinvoq |
| Galderma Laboratories, L.P. | $839.35 | 2019-2025 | Nemluvio, Aklief, Oracea |
| E.R. Squibb & Sons, L.L.C. | $793.35 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $682.45 | 2020-2025 | Ilumya, Absorica Ld, Winlevi |
| Dermavant Sciences, INC. | $669.41 | 2023-2024 | Vtama |
| Amgen INC. | $667.61 | 2021-2025 | Otezla, Otezla |
| Pfizer INC. | $623.98 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $538.01 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $531.13 | 2024-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $514.74 | 2019-2025 | Libtayo, Dupixent |
| Janssen Biotech, INC. | $496.78 | 2022-2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $320.46 | 2023-2025 | Siliq, Jublia, Arazlo |
| Ucb, INC. | $243.79 | 2019-2025 | Bimzelx |
| Incyte Corporation | $192.91 | 2022-2025 | Opzelura |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $175.09 | 2022-2025 | Taltz, Ebglyss |
| Mayne Pharma Commercial LLC | $154.58 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $141.26 | 2023-2025 | |
| Sensus Healthcare, INC. | $122.72 | 2020 | |
| Genzyme Corporation | $121.26 | 2023-2025 | |
| Celgene Corporation | $111.88 | 2019 | |
| Merz North America, INC. | $109.10 | 2022-2025 | |
| Almirall LLC | $105.98 | 2022-2025 | Seysara, Klisyri |
| Vyne Pharmaceuticals INC. | $87.29 | 2020 | |
| Lnhc, INC | $46.04 | 2025 | Zelsuvmi |
| Verrica Pharmaceuticals INC. | $34.84 | 2023-2024 | Ycanth |
| Organon LLC | $33.10 | 2025 | Vtama |
| Catheter Precision, INC. Fka Ra Medical Systems, INC. | $27.50 | 2019 | |
| Cipher Pharmaceuticals US LLC | $27.50 | 2025 | Spinosad, Natroba |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.21 | 2022 | |
| Medimetriks Pharmaceuticals, INC. | $24.60 | 2023 | |
| Journey Medical Corporation | $23.51 | 2022 | |
| Fidia Pharma USA INC. | $20.20 | 2025 | |
| Revance Therapeutics, INC. | $19.75 | 2025 | Daxxify |
| Dermira, INC. | $16.59 | 2020 | |
| Aclaris Therapeutics, INC. | $15.27 | 2019 | |
| Medline Industries LP | $12.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Adler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.